Printer Friendly

GYNEX BEGINS AIDS PATIENT TESTING OF POTENTIAL NEW DRUG THERAPY

 GYNEX BEGINS AIDS PATIENT TESTING OF POTENTIAL NEW DRUG THERAPY
 VERNON HILLS, Ill., Aug. 12 /PRNewswire/ -- Gynex Pharmaceuticals, Inc. (NASDAQ: GYNX) today announced it has begun a multicenter, placebo controlled clinical study of its drug Oxandrin (tm) (Oxandrolone) for the treatment of AIDS patients suffering from HIV-associated muscle weakness.
 The company expects the study to determine the drug's safety and effectiveness in restoring body mass and muscle strength to AIDS patients. The study follows an Investigational New Drug (IND) application submitted to the Food and Drug Administration (FDA), and results are expected by early 1993. The FDA has designated Oxandrin as an orphan drug for HIV wasting syndrome, and Gynex also intends to test Oxandrin as a potential treatment for these patients.
 HIV AND AIDS INCIDENCE
 According to the U.S. Public Health Service, by 1993, AIDS may become the disease causing the greatest loss of human potential in the United States. The U.S. Centers for Disease Control estimates at at least one million Americans are infected with HIV and more than 200,000 AIDS cases have been reported to date.
 OXANDRIN STUDY DESCRIPTION AND OBJECTIVE
 ''Based on the pharmacologic action of Oxandrin, published medical literature and discussions with AIDS experts, we believe that this drug may become an important therapy for both HIV-associated muscle weakness and HIV wasting syndrome,'' said Robert E. Dudley, Ph.D., Gynex vice president of research and development. ''Oxandrin may help reverse the progressive loss of appetite, weight and muscle strength associated with AIDS. The purpose of controlled clinical trials in patients suffering from these conditions is to develop scientific evidence for submission to the FDA of a new drug application, which will seek approval to market Oxandrin for use by HIV infected and AIDS patients.''
 Forty-eight patients will participate in the 16-week study of Oxandrin for HIV-associated muscle weakness under the direction of Dr. Joseph R. Berger, professor of neurology and internal medicine, University of Miami. The other study centers include Mt. Sinai Medical Center in New York and the University of North Carolina at Chapel Hill.
 Gynex Pharmaceuticals is a research-based pharmaceutical company that develops and markets products for use in endocrinology, urology, metabolism, AIDS, and gynecology.
 -0- 8/12/92
 /CONTACT: Stephen Simes, 708-913-1144 of Gynex Pharmaceuticals; or Lynne Franklin of the Financial Relations Board 312-266-7800 for Gynex Pharmaceuticals/
 (GYNX) CO: Gynex Pharmaceuticals, Inc. ST: Illinois IN: MTC SU:


DC -- NY031 -- 9329 08/12/92 10:35 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 12, 1992
Words:407
Previous Article:AMERICAN OIL AND GAS ANNOUNCES EARNINGS FOR THE SECOND QUARTER AND THE SIX MONTHS ENDED JUNE 30, 1992
Next Article:KILLEARN PROPERTIES ANNOUNCES RESULTS
Topics:


Related Articles
GYNEX BEGINS PHASE III TRIAL OF POTENTIAL NEW TESTOSTERONE THERAPY
GYNEX RECEIVES FDA APPROVAL OF TREATMENT IND FOR USE OF OXANDRIN(TM) IN GROWTH DISORDER
GYNEX PHARMACEUTICALS ANNOUNCES FIRST ORAL DRUG FOR TURNER SYNDROME
HOFFMANN-LA ROCHE TO PURSUE RESEARCH DESPITE DEMONSTRATION
GYNEX DRUG CUTS DEATH RATE IN ALCOHOLIC HEPATITIS STUDY; GYNEX PLANS TO INCLUDE RESULTS IN FDA SUBMISSION BY THE END OF 1993
US FDA AUTHORIZES CELGENE TO PROVIDE EXPANDED ACCESS TO SYNOVIR (THALIDOMIDE) FOR AIDS-ASSOCIATED WASTING
CELL GENESYS COMPLETES ENROLLMENT IN T CELL GENE THERAPY TRIAL FOR AIDS
EXCITING RESULTS WITH MERCK'S CRIXIVAN(R) COULD CHANGE THE WAY DOCTORS TREAT HIV DISEASE AND AIDS
CELL GENESYS FILES IND FOR EXPANDED AIDS GENE THERAPY TRIALS
CELL GENESYS CLEARS FDA FOR EXPANDED AIDS GENE THERAPY TRIALS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters